PubRank

Markku S Nieminen

Author PubWeight™ 362.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010 28.21
2 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 23.18
3 Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010 23.08
4 Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 2010 20.01
5 Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012 12.10
6 Third universal definition of myocardial infarction. J Am Coll Cardiol 2012 8.59
7 Third universal definition of myocardial infarction. Circulation 2012 8.47
8 Third universal definition of myocardial infarction. Eur Heart J 2012 7.98
9 Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet 2010 7.94
10 Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 7.75
11 Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2012 7.59
12 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 6.87
13 A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet 2009 6.31
14 A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet 2010 6.07
15 Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004 3.88
16 Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003 3.78
17 Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002 3.70
18 Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004 3.68
19 State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008 3.35
20 Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005 3.27
21 Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet 2013 3.25
22 Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet 2012 3.21
23 The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004 2.96
24 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007 2.90
25 Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005 2.69
26 The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008 2.65
27 Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004 2.56
28 Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003 2.48
29 Genetically determined height and coronary artery disease. N Engl J Med 2015 2.24
30 Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial. Am Heart J 2006 2.19
31 Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med 2003 2.09
32 Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006 2.00
33 Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006 1.80
34 A novel mutation, Ser143Pro, in the lamin A/C gene is common in finnish patients with familial dilated cardiomyopathy. Eur Heart J 2004 1.78
35 Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009 1.76
36 Evidence-based use of levosimendan in different clinical settings. Eur Heart J 2006 1.73
37 Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet 2013 1.72
38 Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002 1.69
39 Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study. J Hypertens 2003 1.69
40 Predictive value of electrocardiographic QT interval and T-wave morphology parameters for all-cause and cardiovascular mortality in a general population sample. Heart Rhythm 2009 1.68
41 Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003 1.65
42 Coronary artery disease-associated locus on chromosome 9p21 and early markers of atherosclerosis. Arterioscler Thromb Vasc Biol 2008 1.62
43 Relationship of common candidate gene variants to electrocardiographic T-wave peak to T-wave end interval and T-wave morphology parameters. Heart Rhythm 2010 1.58
44 Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Circ Arrhythm Electrophysiol 2008 1.56
45 Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015 1.56
46 Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004 1.53
47 Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2004 1.52
48 Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002 1.51
49 Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension 2005 1.49
50 Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2009 1.48
51 Early familial dilated cardiomyopathy: identification with determination of disease state parameter from cine MR image data. Radiology 2008 1.48
52 Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010 1.46
53 Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens 2008 1.46
54 Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med 2011 1.45
55 Quantifying cardiac hemodynamic stress and cardiomyocyte damage in ischemic and nonischemic acute heart failure. Circ Heart Fail 2011 1.44
56 Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens 2008 1.44
57 Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J 2005 1.44
58 Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007 1.41
59 Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens 2016 1.41
60 Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hypertens 2006 1.39
61 Magnetocardiographic indices of left ventricular hypertrophy. J Hypertens 2002 1.38
62 Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009 1.25
63 QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2004 1.25
64 Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2004 1.21
65 Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens 2002 1.21
66 APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res 2004 1.16
67 Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005 1.14
68 Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 2004 1.12
69 Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003 1.12
70 Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002 1.11
71 Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Eur Heart J 2003 1.11
72 Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007 1.09
73 High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med 2009 1.08
74 Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J Clin Endocrinol Metab 2013 1.07
75 Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010 1.06
76 Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press 2004 1.04
77 Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail 2008 1.03
78 Two novel mutations in the beta-myosin heavy chain gene associated with dilated cardiomyopathy. Eur J Heart Fail 2004 1.03
79 Salivary biomarkers of bacterial burden, inflammatory response, and tissue destruction in periodontitis. J Clin Periodontol 2014 1.03
80 Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 2012 1.03
81 A common periodontal pathogen has an adverse association with both acute and stable coronary artery disease. Atherosclerosis 2012 1.02
82 Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease. Am J Cardiol 2006 1.01
83 Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. Circulation 2005 1.00
84 QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. Eur Heart J 2009 1.00
85 Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy). Am J Cardiol 2005 0.97
86 Metabolic syndrome and carotid intima media thickness in the Health 2000 Survey. Atherosclerosis 2008 0.97
87 Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002 0.96
88 Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006 0.94
89 Relationship of electrocardiographic repolarization measures to echocardiographic left ventricular mass in men with hypertension. J Hypertens 2007 0.94
90 Interleukin-6 promoter polymorphism and cardiovascular risk factors: the Health 2000 Survey. Atherosclerosis 2009 0.93
91 R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis 2004 0.93
92 Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002 0.92
93 Prevalence of ventricular conduction blocks in the resting electrocardiogram in a general population: the Health 2000 Survey. Int J Cardiol 2012 0.92
94 In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press 2010 0.92
95 A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy. J Mol Med (Berl) 2003 0.92
96 Cardiac steatosis and left ventricular function in men with metabolic syndrome. J Cardiovasc Magn Reson 2013 0.92
97 Periodontitis is associated with angiographically verified coronary artery disease. J Clin Periodontol 2011 0.91
98 Long-term survival after hospitalization for acute heart failure--differences in prognosis of acutely decompensated chronic and new-onset acute heart failure. Int J Cardiol 2012 0.90
99 Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey. Metab Syndr Relat Disord 2011 0.90
100 Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007 0.90
101 Cohort Profile: the Corogene study. Int J Epidemiol 2011 0.89
102 A novel functional polymorphism in the PECAM-1 gene (53G>A) is associated with progression of atherosclerosis in the LOCAT and REGRESS studies. Atherosclerosis 2003 0.89
103 Genome-wide meta-analysis of common variant differences between men and women. Hum Mol Genet 2012 0.88
104 In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens 2010 0.87
105 Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). Am J Cardiol 2004 0.86
106 Predictive value of electrocardiographic T-wave morphology parameters and T-wave peak to T-wave end interval for sudden cardiac death in the general population. Circ Arrhythm Electrophysiol 2013 0.86
107 Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. Hypertension 2003 0.85
108 Outcome up to one year following different reperfusion strategies in acute ST-segment elevation myocardial infarction: the Helsinki-Uusimaa Hospital District registry of ST-Elevation Acute Myocardial Infarction (HUS-STEMI). Eur Heart J Acute Cardiovasc Care 2013 0.85
109 Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens 2002 0.85
110 The COACH risk engine: a multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail 2011 0.85
111 [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]. Rev Esp Cardiol 2005 0.85
112 Insulin resistance as predictor of the angiographic severity and extent of coronary artery disease. Ann Med 2007 0.84
113 Home-measured blood pressure is more strongly associated with atherosclerosis than clinic blood pressure: the Finn-HOME Study. J Hypertens 2007 0.84
114 Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail 2008 0.84
115 The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J Clin Hypertens (Greenwich) 2005 0.84
116 Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin 2007 0.84
117 Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. Eur J Cardiovasc Prev Rehabil 2009 0.84
118 Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr Metab Cardiovasc Dis 2007 0.83
119 Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study. Am Heart J 2008 0.83
120 Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction. Atherosclerosis 2012 0.83
121 Is periodontal infection behind the failure of antibiotics to prevent coronary events? Atherosclerosis 2006 0.83
122 Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D and S65C in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005 0.83
123 Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Circulation 2009 0.83
124 Low normal level of protein C or of antithrombin increases risk for recurrent cardiovascular events. Blood Coagul Fibrinolysis 2005 0.82
125 Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes. Ann Med 2013 0.82
126 Relation of twelve-lead electrocardiographic T-wave morphology descriptors to left ventricular mass. Am J Cardiol 2002 0.82
127 Epicardial fat, cardiac dimensions, and low-grade inflammation in young adult monozygotic twins discordant for obesity. Am J Cardiol 2012 0.82
128 Chlamydial lipopolysaccharide is present in serum during acute coronary syndrome and correlates with CRP levels. Atherosclerosis 2006 0.81
129 Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy. Am J Hypertens 2012 0.81
130 The association of serum neutrophil markers and acute coronary syndrome. Scand J Immunol 2012 0.81
131 Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study. Hypertension 2006 0.81
132 Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. Am Heart J 2003 0.81
133 A meta-analysis of genome-wide association studies of the electrocardiographic early repolarization pattern. Heart Rhythm 2012 0.81
134 Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population. Ann Med 2012 0.81
135 Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 2002 0.81
136 [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. Ital Heart J Suppl 2005 0.80
137 Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. Am J Hypertens 2008 0.80
138 Association of variation in the interleukin-1 gene family with diabetes and glucose homeostasis. J Clin Endocrinol Metab 2009 0.80
139 Chlamydia pneumoniae DNA is present in peripheral blood mononuclear cells during acute coronary syndrome and correlates with chlamydial lipopolysaccharide levels in serum. Scand J Infect Dis 2009 0.79
140 Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study. J Hypertens 2007 0.79
141 Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. Blood Press 2009 0.79
142 ECG left ventricular hypertrophy is a stronger risk factor for incident cardiovascular events in women than in men in the general population. J Hypertens 2015 0.79
143 A common variant near the KCNJ2 gene is associated with T-peak to T-end interval. Heart Rhythm 2012 0.78
144 Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction. Cardiovasc Res 2003 0.78
145 The use of more than one inotrope in acute heart failure is associated with increased mortality: a multi-centre observational study. Acute Card Care 2008 0.78
146 Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. Ann Med 2009 0.78
147 Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study. Am J Hypertens 2008 0.78
148 Mortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol 2012 0.78
149 Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 2005 0.78
150 Prognostic implications of intraventricular conduction delays in a general population: the Health 2000 Survey. Ann Med 2015 0.78
151 Subgingival bacterial burden in relation to clinical and radiographic periodontal parameters. J Periodontol 2013 0.77
152 Prognostic implications of quantitative ST-segment characteristics and T-wave amplitude for cardiovascular mortality in a general population from the Health 2000 Survey. Ann Med 2010 0.77
153 Gender differences in the treatment and secondary prevention of CHD at population level. Scand Cardiovasc J 2005 0.77
154 Genetic variation on the BAT1-NFKBIL1-LTA region of major histocompatibility complex class III associates with periodontitis. Infect Immun 2014 0.77
155 Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study. Eur J Heart Fail 2011 0.77
156 Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy. Am J Hypertens 2005 0.77
157 Clarithromycin reduces recurrent cardiovascular events in subjects without periodontitis. Atherosclerosis 2006 0.77
158 Oral levosimendan improves filling pressure and systolic function during long-term treatment. Scand Cardiovasc J 2011 0.77
159 A new common mutation in the cardiac beta-myosin heavy chain gene in Finnish patients with hypertrophic cardiomyopathy. Ann Med 2014 0.77
160 Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opin Emerg Drugs 2005 0.77
161 Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis 2004 0.77
162 Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain. Ann Med 2013 0.77
163 Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. Am J Hypertens 2003 0.77
164 Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study. J Hypertens 2008 0.77
165 Novel enzyme immunoassay utilizing lipopolysaccharide-binding protein as a capture molecule for the measurement of chlamydial lipopolysaccharide in serum. Diagn Microbiol Infect Dis 2005 0.77
166 Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hypertens 2012 0.77
167 An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. Clin Ther 2003 0.76
168 Lessons from Lisbon on AHF drug treatment: is it really true that all-old-failed-all-new-will-succeed? Int J Cardiol 2013 0.76
169 Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens 2010 0.76
170 Cardiac findings of reactive arthritis: an observational echocardiographic study. Rheumatol Int 2002 0.76
171 Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy. J Hypertens 2011 0.76
172 Management of acute heart failure and the effect of systolic blood pressure on the use of intravenous therapies. Eur Heart J Acute Cardiovasc Care 2013 0.76
173 Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). Am J Cardiol 2005 0.76
174 Soluble tumor necrosis factor receptor levels identify a subgroup of heart failure patients with increased cardiomyocyte apoptosis. Clin Chim Acta 2002 0.75
175 Correction: The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genet 2016 0.75
176 Heart failure in the elderly: how risky is it to be discharged? Eur J Heart Fail 2008 0.75
177 Comparison of the SCOPE and LIFE results. J Hypertens 2003 0.75
178 Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease. Clin Vaccine Immunol 2007 0.75
179 The type of acute heart failure and the costs of hospitalization. Int J Cardiol 2009 0.75
180 Predicting recovery of myocardial function by electrocardiography after acute infarction. Ann Noninvasive Electrocardiol 2012 0.75
181 Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study. Am J Hypertens 2007 0.75
182 The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005 0.75
183 Stimulated release of endothelin-converting enzyme is simultaneous with tissue-type plasminogen activator and decrease in coronary heart disease. Scand Cardiovasc J 2002 0.75
184 Novel 6p21.3 Risk Haplotype Predisposes to Acute Coronary Syndrome. Circ Cardiovasc Genet 2015 0.75
185 Clinical findings, outcome and treatment in patients > or = 75 years with acute myocardial infarction. Eur J Epidemiol 2003 0.75
186 The clinical effects of levosimendan are not attenuated by sulfonylureas. Scand Cardiovasc J 2012 0.75
187 Clinical usefulness of bronchoalveolar lavage in heart transplant recipients with suspected lower respiratory tract infection. J Heart Lung Transplant 2004 0.75
188 [Treatment and care of coronary artery syndrome in Finland]. Duodecim 2005 0.75
189 Subgingival Aggregatibacter actinomycetemcomitans associates with the risk of coronary artery disease. J Clin Periodontol 2013 0.75
190 Beneficial effect of clarithromycin in patients with acute coronary syndrome and complement C4 deficiencies. Scand Cardiovasc J 2009 0.75
191 Prevalence and prognostic value of poor R-wave progression in standard resting electrocardiogram in a general adult population. The Health 2000 Survey. Ann Med 2010 0.75
192 Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study. Am J Hypertens 2012 0.75